In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1.     IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ·        Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated ·        Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated ·        Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated ·        High risk: His ..read more

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center.  RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/ FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4: https://www.youtube.com/watch?v=VSjdGeeXb40 ..read more

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.  ..read more

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel.  Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis   https://ash.confex.com/ash/2023/webprogram/Paper173509.html   2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with ..read more

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode:  First, we will focus on a few abstracts in precursor states, MGUS.  1.      New diagnostic criteria for light chain MGUS (IStopMM):               https://ash.confex.com/ash/2023/webprogram/Paper188547.html              https://ash.confex.com/ash/2023/webprogram/Paper182661.html 2.     PERSEUS Trial-Dara-VR ..read more

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:  1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/   2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL: https://pubmed.ncbi.nlm.nih.gov/31451445/   3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36548927/   4. Phase 2 trial of mosunetuzumab in relapsed/refra ..read more

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML  https://www.nejm.org/doi/full/10.1056/nejmoa1507471   2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nejm.org/doi/full/10.1056/nejmoa1614359   3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-bl ..read more

In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza.  We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair.  Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/dp/1541699521 ..read more

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.  Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:  https://x.com/Rfonsi1/status/1206004966294294528?s=20   2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs: https://pubmed.ncbi.nlm.nih.gov/28655925/   3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers): https://pubmed.n ..read more

In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes:  1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1    2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds – https://ashpublications.org/blood/article/140/Supplement%201/1773/493224/High-Dose-Chemotherapy-and-Autologous-Stem-Cell?searchresult=1    3. IESLG 32 study (MATRIX) - https ..read more